Literature DB >> 22847000

Curcumin inhibits Rift Valley fever virus replication in human cells.

Aarthi Narayanan1, Kylene Kehn-Hall, Svetlana Senina, Lindsay Lundberg, Rachel Van Duyne, Irene Guendel, Ravi Das, Alan Baer, Laura Bethel, Michael Turell, Amy Lynn Hartman, Bhaskar Das, Charles Bailey, Fatah Kashanchi.   

Abstract

Rift Valley fever virus (RVFV) is an arbovirus that is classified as a select agent, an emerging infectious virus, and an agricultural pathogen. Understanding RVFV-host interactions is imperative to the design of novel therapeutics. Here, we report that an infection by the MP-12 strain of RVFV induces phosphorylation of the p65 component of the NFκB cascade. We demonstrate that phosphorylation of p65 (serine 536) involves phosphorylation of IκBα and occurs through the classical NFκB cascade. A unique, low molecular weight complex of the IKK-β subunit can be observed in MP-12-infected cells, which we have labeled IKK-β2. The IKK-β2 complex retains kinase activity and phosphorylates an IκBα substrate. Inhibition of the IKK complex using inhibitors impairs viral replication, thus alluding to the requirement of an active IKK complex to the viral life cycle. Curcumin strongly down-regulates levels of extracellular infectious virus. Our data demonstrated that curcumin binds to and inhibits kinase activity of the IKK-β2 complex in infected cells. Curcumin partially exerts its inhibitory influence on RVFV replication by interfering with IKK-β2-mediated phosphorylation of the viral protein NSs and by altering the cell cycle of treated cells. Curcumin also demonstrated efficacy against ZH501, the fully virulent version of RVFV. Curcumin treatment down-regulated viral replication in the liver of infected animals. Our data point to the possibility that RVFV infection may result in the generation of novel versions of host components (such as IKK-β2) that, by virtue of altered protein interaction and function, qualify as unique therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847000      PMCID: PMC3460426          DOI: 10.1074/jbc.M112.356535

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  BFV activates the NF-kappaB pathway through its transactivator (BTas) to enhance viral transcription.

Authors:  Jian Wang; Juan Tan; Xihui Zhang; Hongyan Guo; Qicheng Zhang; Tingting Guo; Yunqi Geng; Wentao Qiao
Journal:  Virology       Date:  2010-02-23       Impact factor: 3.616

2.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Rift Valley fever virus.

Authors:  Ramon Flick; Michèle Bouloy
Journal:  Curr Mol Med       Date:  2005-12       Impact factor: 2.222

4.  Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation.

Authors:  Q Sun; H Matta; G Lu; P M Chaudhary
Journal:  Oncogene       Date:  2006-05-04       Impact factor: 9.867

5.  Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression.

Authors:  Chuan-tao Tu; Bing Han; Qun-yan Yao; Yi-an Zhang; Hong-chun Liu; Shun-cai Zhang
Journal:  Int Immunopharmacol       Date:  2011-12-02       Impact factor: 4.932

Review 6.  Advances in Rift Valley fever research: insights for disease prevention.

Authors:  A Desiree LaBeaud; James W Kazura; Charles H King
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

Review 7.  Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax.

Authors:  C A Pise-Masison; R Mahieux; M Radonovich; H Jiang; J Duvall; C Guillerm; J N Brady
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

8.  Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation.

Authors:  D Pan; L-Z Pan; R Hill; P Marcato; M Shmulevitz; L T Vassilev; P W K Lee
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

9.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

10.  Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation.

Authors:  S M Wyke; S T Russell; M J Tisdale
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

View more
  27 in total

Review 1.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

Review 2.  Systems biology unravels interferon responses to respiratory virus infections.

Authors:  Andrea L Kroeker; Kevin M Coombs
Journal:  World J Biol Chem       Date:  2014-02-26

Review 3.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

4.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

5.  The ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infection.

Authors:  Moushimi Amaya; Forrest Keck; Michael Lindquist; Kelsey Voss; Lauren Scavone; Kylene Kehn-Hall; Brian Roberts; Charles Bailey; Connie Schmaljohn; Aarthi Narayanan
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

6.  Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease.

Authors:  Petrus Jansen van Vuren; Sharon Shalekoff; Antoinette A Grobbelaar; Brett N Archer; Juno Thomas; Caroline T Tiemessen; Janusz T Paweska
Journal:  Virol J       Date:  2015-10-06       Impact factor: 4.099

7.  Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection.

Authors:  Ashwini Benedict; Neha Bansal; Svetlana Senina; Idris Hooper; Lindsay Lundberg; Cynthia de la Fuente; Aarthi Narayanan; Bradford Gutting; Kylene Kehn-Hall
Journal:  Front Microbiol       Date:  2015-07-08       Impact factor: 5.640

8.  Curcumin inhibits the replication of enterovirus 71 in vitro.

Authors:  Ying Qin; Lexun Lin; Yang Chen; Shuo Wu; Xiaoning Si; Heng Wu; Xia Zhai; Yan Wang; Lei Tong; Bo Pan; Xiaoyan Zhong; Tianying Wang; Wenran Zhao; Zhaohua Zhong
Journal:  Acta Pharm Sin B       Date:  2014-07-24       Impact factor: 11.413

9.  The role of IKKβ in Venezuelan equine encephalitis virus infection.

Authors:  Moushimi Amaya; Kelsey Voss; Gavin Sampey; Svetlana Senina; Cynthia de la Fuente; Claudius Mueller; Valerie Calvert; Kylene Kehn-Hall; Calvin Carpenter; Fatah Kashanchi; Charles Bailey; Soren Mogelsvang; Emanuel Petricoin; Aarthi Narayanan
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

10.  Curcumin protects against ischemic spinal cord injury: The pathway effect.

Authors:  Jinhua Zhang; Hao Wei; Meimei Lin; Chunmei Chen; Chunhua Wang; Maobai Liu
Journal:  Neural Regen Res       Date:  2013-12-25       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.